221 related articles for article (PubMed ID: 32993957)
1. ARHGEF19 regulates MAPK/ERK signaling and promotes the progression of small cell lung cancer.
Wang Z; Kan G; Sheng C; Yao C; Mao Y; Chen S
Biochem Biophys Res Commun; 2020 Dec; 533(4):792-799. PubMed ID: 32993957
[TBL] [Abstract][Full Text] [Related]
2. ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.
Li Y; Ye Z; Chen S; Pan Z; Zhou Q; Li YZ; Shuai WD; Kuang CM; Peng QH; Shi W; Mao X; Liu RY; Huang W
Int J Cancer; 2018 Apr; 142(7):1379-1391. PubMed ID: 29164615
[TBL] [Abstract][Full Text] [Related]
3. microRNA-195 Promotes Small Cell Lung Cancer Cell Apoptosis via Inhibiting Rap2C Protein-Dependent MAPK Signal Transduction.
Tong J; Lu J; Yin Y; Wang Y; Zhang K
Technol Cancer Res Treat; 2020; 19():1533033820977546. PubMed ID: 33302819
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways.
Wan J; Wu W
J Exp Clin Cancer Res; 2016 Jul; 35(1):119. PubMed ID: 27456341
[TBL] [Abstract][Full Text] [Related]
6. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
7. ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21
Zhang Q; Zheng L; Bai Y; Su C; Che Y; Xu J; Sun K; Ni J; Huang L; Shen Y; Jia L; Xu L; Yin R; Li M; Hu J
Cancer Lett; 2023 Nov; 577():216426. PubMed ID: 37820992
[TBL] [Abstract][Full Text] [Related]
8. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract][Full Text] [Related]
9. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
Alam SK; Wang L; Ren Y; Hernandez CE; Kosari F; Roden AC; Yang R; Hoeppner LH
Br J Cancer; 2020 Sep; 123(5):819-832. PubMed ID: 32499571
[TBL] [Abstract][Full Text] [Related]
10. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
11. Friend leukemia virus integration 1 promotes tumorigenesis of small cell lung cancer cells by activating the miR-17-92 pathway.
Li L; Song W; Yan X; Li A; Zhang X; Li W; Wen X; Zhou L; Yu D; Hu JF; Cui J
Oncotarget; 2017 Jun; 8(26):41975-41987. PubMed ID: 28410216
[TBL] [Abstract][Full Text] [Related]
12. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
14. RET mutation and expression in small-cell lung cancer.
Dabir S; Babakoohi S; Kluge A; Morrow JJ; Kresak A; Yang M; MacPherson D; Wildey G; Dowlati A
J Thorac Oncol; 2014 Sep; 9(9):1316-23. PubMed ID: 25122427
[TBL] [Abstract][Full Text] [Related]
15. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
16. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
[TBL] [Abstract][Full Text] [Related]
17. The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer.
Szczepny A; Rogers S; Jayasekara WSN; Park K; McCloy RA; Cochrane CR; Ganju V; Cooper WA; Sage J; Peacock CD; Cain JE; Burgess A; Watkins DN
Oncogene; 2017 Sep; 36(39):5544-5550. PubMed ID: 28581526
[TBL] [Abstract][Full Text] [Related]
18. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J; Cao D; Sha J; Zhu X; Han S
Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
[TBL] [Abstract][Full Text] [Related]
19. Critical role of G(alpha)12 and G(alpha)13 for human small cell lung cancer cell proliferation in vitro and tumor growth in vivo.
Grzelinski M; Pinkenburg O; Büch T; Gold M; Stohr S; Kalwa H; Gudermann T; Aigner A
Clin Cancer Res; 2010 Mar; 16(5):1402-15. PubMed ID: 20160064
[TBL] [Abstract][Full Text] [Related]
20. Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Cristea S; Sage J
J Thorac Oncol; 2016 Aug; 11(8):1233-1241. PubMed ID: 27133774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
